# Study of Sorafenib in Patients With Advanced Renal Cell Carcinoma

> **NCT00848640** · PHASE2 · COMPLETED · sponsor: **Egyptian Foundation For Cancer Research** · enrollment: 75 (actual)

## Conditions studied

- Metastatic Renal Cell Carcinoma

## Interventions

- **DRUG:** Sorafenib

## Key facts

- **NCT ID:** NCT00848640
- **Lead sponsor:** Egyptian Foundation For Cancer Research
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2009-12
- **Final completion:** 2010-03
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2010-05-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00848640

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00848640, "Study of Sorafenib in Patients With Advanced Renal Cell Carcinoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00848640. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*